Newly Merged Japanese Firm Files For First Drug Approval In China
This article was originally published in PharmAsia News
Executive Summary
Japan's Kyowa Hakko Kirin applied for approval of its allergy drug in China as part of an effort to expand business there. Kyowa Hakko Kogyo and Kirin Pharma merged in October as a way for the former company to enlarge is presence in China. The first drug the new firm seeks to market is Allelock (olopatadine) antihistamine. Since the drug already is approved in Japan, under Chinese rules Allelock needs to undergo only a Phase III trial, enabling it to reach the Chinese market in 2010. (Click here for more - a subscription may be required